How do tumor cells respond to HDAC inhibition?

FEBS J 2016 11 10;283(22):4032-4046. Epub 2016 May 10.

Cancer Therapeutics Program, The Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.

It is now well recognized that mutations, deregulated expression, and aberrant recruitment of epigenetic readers, writers, and erasers are fundamentally important processes in the onset and maintenance of many human tumors. The molecular, biological, and biochemical characteristics of a particular class of epigenetic erasers, the histone deacetylases (HDACs), have been extensively studied and small-molecule HDAC inhibitors (HDACis) have now been clinically approved for the treatment of human hemopoietic malignancies. This review explores our current understanding of the biological and molecular effects on tumor cells following HDACi treatment. The predominant responses include induction of tumor cell death and inhibition of proliferation that in experimental models have been linked to therapeutic efficacy. However, tumor cell-intrinsic responses to HDACi, including modulating tumor immunogenicity have also been described and may have substantial roles in mediating the antitumor effects of HDACi. We posit that the field has failed to fully reconcile the biological consequences of exposure to HDACis with the molecular events that underpin these responses, however progress is being made. Understanding the pleiotrophic activities of HDACis on tumor cells will hopefully fast track the development of more potent and selective HDACi that may be used alone or in combination to improve patient outcomes.

Download full-text PDF

Source
http://doi.wiley.com/10.1111/febs.13746
Publisher Site
http://dx.doi.org/10.1111/febs.13746DOI Listing
November 2016
3 Reads

Publication Analysis

Top Keywords

tumor cells
12
tumor
6
approved treatment
4
treatment human
4
substantial roles
4
roles mediating
4
described substantial
4
clinically approved
4
immunogenicity described
4
modulating tumor
4
review explores
4
malignancies review
4
tumor immunogenicity
4
hdacis clinically
4
hemopoietic malignancies
4
human hemopoietic
4
mediating antitumor
4
posit field
4
extensively studied
4
hdacs extensively
4

Similar Publications